The Digital Clinic for Neurodevelopmental and related mental disorders designed and dedicated to children and adolescents. Neurodevelopmental disorders and associated mental health disturbances constitute the 1st major health condition in youth. Today, 1 out of 6 children have neurodevelopmental disorders and associated mental health disturbances. However, only 8% are diagnosed and 6% pursue therapies due to complex clinical diagnostic, a shortage of health practitioners and high costs. We develop holistic e-assessment and monitoring applications, that rely on digital epidemiology and combine gamification, biomarkers and emerging technologies such as artificial intelligence to help diagnosis and therapeutic orientation. We bring cutting-edge technologies beyond the labs to unlock brain development in children and adolescents. These technologies underlying our innovations have been around for decades, but only now with O-Kidia, children, parents and healthcare practitioners can access and benefit from them. Similarly to a blood test result, we want our solutions to substitute the current questionnaires but not the health practitioner's expertise to save time, guide towards the most relevant therapy/practitioners, and be cost-effective. Get to know your brain to give more meaningful time to relationship

1. The Digital Clinic
for Neurodevelopmental Disorders
dedicated to Children and Adolescents
O-Kidia™ 2022 | Non-Confidential

2. Neurodevelopmental & related mental disorders, a societalissue
« are characterized by early-onset deficits of variable severity in
personal, social, academic, or occupational functioning»
Rank 1st
Among disorders
in youth
+9M
Of children &
adolescents
(OCDE, 2022)
8% are
diagnosed
6% undergo a
therapy
65% have more than
1 comorbidity
1 child out of 6
(15% suffer from clinically significant illness)
FACTS
Lost of self-confidence, self-esteem
Poorer educational attainment , and later
employment
Interpersonal difficulties, exclusion up to
increased risk of suicides & mortality
MULTIPLE NEGATIVE IMPACTS
O-Kidia™ 2022 | Non-Confidential
Adverse & long-lasting effects

3. Public Health
issue
Covid-19
As a booster
SERIOUS PROBLEMS
but ADDRESSABLE
A long obstacle course
1st signs
Diagnostic
18 – 24 months
Age
average
8 yrs
Economic
burden
Medical
inequality
15 pedopsychiatrists/
100 000 people
Lack of
healthcare
providers
Too much
visits
Few digital tools
available
Devastating
impacts
Long waits
O-Kidia™ 2022 | Non-Confidential
Neuro-Developpemental & related mental disorders

4. Faster and more relevant access to
diagnosis
Better targeting to the most
appropriate therapy Empowering connected physicians to e-patients
Increase care quality
Parents wish to access knowledge
and an effective healthcare
ecosystem
Healthcare providers want to
provide a better care accounting for
their knowledge and an optimal care
resources
Save time for pre-diagnosis
From diagnosis to innovative therapeutic solutions
CHARTE GRAPHIQUE. LOGOS
O-Kidia™ 2022 | Non-Confidential

5. Simpler, Faster, Better
Multi-flux capture
(video, digit, sound)
Games
Passive digital
phenotyping
Clinical data
Émotion
Attention
Qualité de vie
Interaction sociales
Renseignements
complémentaires
Profils des patients similaires
Envie d’en apprendre plus ?
Examens complémentaires
Pédopsychiatre
Psychomotricien
Orthoptiste
Troubles de l’anxiété
Troubles des déficits de l’attention
Troubles du comportement social
Prénom
Nom
Age
Renseignements
complémentaires
Profils des patients similaires
Lorem Ipsum
Examens complémentaires
Pédopsychiatre
Psychomotricien
Orthoptiste
Troubles de l’anxiété
Troubles des déficits de l’attention
Troubles du comportement social
Prénom
Nom
Age
Émotion
Attention
Valeur : 56%
Moyenne : 53,2%
Détails
Valeur : 45%
Moyenne : 49,8%
Détails
Évaluations
Combine digital (bio)markers and clinical data – Digital Epidemiology
Emotion, z-score
Cognition, z-score
Comportement,
z-score
ASD
CSD
SLD
ADHD
DCD
AI Algorithms
O-Kidia™ 2022 | Non-Confidential
« Blood test » providers
for mental states

6. A missing value within the existing ecosystem
Scholar
abilities Attention
TSA
Anxiety, stress,
depression (39.8M £)
ADHD
(301M$)
Learning
disabilities
(4.9M€)
(Alzheimer)
(50.4 M$)
Neurological
disorders
(Alzheimer)
(6.6 M$)
Cognitive abilities
(7,6M$)
(8,3M$)
Digital therapeutics, anxiety
PTSD
(409M$, NASDAQ)
(31,8M$)
(910M$)
(113,8M$)
(160M$)
(88,8M$)
(266,7M$)
(120k$)
DIAGNOSTIC THERAPIES MANAGEMENT
Use IA
(53.9 M$)
O-Kidia™ 2022 | Non-Confidential
Attention

7. O-Kidia™ 2022 | Non-Confidential
Commercial model
B2B distribution channel with Healthcare providers
As a prescription, routinely follow-up can be done
B2BC distribution channel for patients with monthly license for API
1 487 Hospitals & clinics
Digital Health Market
234,5 Bds€ in 2023
worldwide
In Europe 50 Bds€ in 2020
107 Healthcare
providers
8 472 Medico-social centers
79 Patients-oriented platforms
50+ Software
editors
42+ Pharma
industries
9 millions Patients
146 non-profit organisations
750 000 Health pratitionners
9 millions Children
European Digital
Mental Heath
Market
4 B€
O-Kidia
9millions youth
Autism
Spectrum
disorders
Neurodevelopmental
disorders
Attention
deficit
disorders
w/wout
Hyperactivity
Motor & Tic
disorders
Specific
Learning
disorders
Communication
disorders
Bipolar
disorders
Schizophrenia
Seizures
Obesity
Psychoses
Anxiety
Sleep
disorders
Drug
Abuse
Affective
disorders
PTSD
Mental Health in Europe, 85 millions individuals
Needs & market size

8. TELEMEDICINE CLINICAL TRIALS DIGITAL THERAPEUTICS
Increasing awareness among key players
Provision of remote clinical services
between the patient and the healthcare
provider, with our platform
Identify and monitor the effects of
under development drugs on the
mental health of patients
Plug to a secure third-party platform for
referring to the most relevant therapy
Paid by the third-party platform (souscription)
Price by test (~ 5 €/mois)
Paid by third-party platform
Commission of 10% by call (~ 3,6€ by call)
Paid by the pharmaceutical industries
To be determined /Upfront paiment
O-Kidia™ 2022 | Non-Confidential

9. Sept 2022 Dec 2023 Dec 2024
First pilots with children & patient
organisations, health
practitionners,
Partnerships EU
Pilot in clinics & hospitals
(Lilab & ARS)
Partnerships US &
internationalisation
Dec 2022 June 2023
HDS analytical
platform v1.0
Industrial production of
the AI- algorithms
Industrial production of
the analytical platform
v2.0
Commercialisation
France/Europe
CE IIa Marking
Clinical study
ANSM
AI-based Patent
May 2022
Pre-clinical study
RCB 2022-A00766-37
O-Kidia 2022 | Non-Confidentiel
Roadmap & Milestones
2nd tech patent
Pre-clinical study in
ADHD children
IDRCB 2021-A02537-34
Multi-flux
gamified battery
CE I Marking
Platform Spectrum EPIDIAI4Kids

10. The founding team Founded in Feb 2022
Géraldine Eberhardt
Gouvernance , legal & growth
Alexandra Carrel
Collaborations R&D
Caroline de Mareüil-Vilette
Industrial & Intellectual Properpties
Samy Bouin
CFO, Accounting
Mélissa Vidal
HR, Scholar
partnerships
Thibault Kine
Web developper
Jean Juillard
Game Designer &
programmer
Ken Polizzi
CTO
Théo Marchand
Assistant research, PhD student
Katia Cataudella
UX/UI designer
Yasmine Samet
Graphic designer
O-Kidia 2022 | Non-Confidentiel
Msc Students
Neuroscience, Cognitive sciences
Vanessa Douet
Vannucci
Founder & CEO
Tony Varnier
Project Manager, Digital Marketing
5 EMSE students
datascientist
Alexandre Hennequin
Senior datascientist

11. Our Ecosystem
O-Kidia™ 2022 | Non-Confidential
Hervé Caci
MD. PhD
Pedo-psychiatrist
CHU Nice
Olivier Oullier
PhD
Neuroscientist President
of EMOTIV Prof AMU
Pascal Staccini
MD, PhD
Medical IT Director
President of NIBN
Marie-Estelle
Carrasco
Global Data Analytic
Excellence - Danone
Diane Purper-Ouakil
MD. PhD
Pedo-Psychiatrist
MPEA Saint Eloi, PUPH
The Ethics & Scientific board
The Partners

12. Vanessa Douet Vannucci
36 boulevard Gorbella, 06 100 Nice
vanessa.douet@o-kidia.com
www.o-kidia.com
O-Kidia™ 2022 | Non-Confidentiel
CHARTE GRAPHIQUE. LOGOS